Annual Cash & Cash Equivalents
$1.51 B
+$624.83 M+70.88%
31 December 2023
Summary:
Jazz Pharmaceuticals annual cash & cash equivalents is currently $1.51 billion, with the most recent change of +$624.83 million (+70.88%) on 31 December 2023. During the last 3 years, it has risen by +$914.86 million (+154.68%). JAZZ annual cash & cash equivalents is now at all-time high.JAZZ Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$2.22 B
+$862.33 M+63.60%
30 September 2024
Summary:
Jazz Pharmaceuticals quarterly cash and cash equivalents is currently $2.22 billion, with the most recent change of +$862.33 million (+63.60%) on 30 September 2024. Over the past year, it has increased by +$711.83 million (+47.26%). JAZZ quarterly cash and cash equivalents is now at all-time high.JAZZ Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +47.3% |
| 3 y3 years | +154.7% | +275.0% |
| 5 y5 years | +136.3% | +248.0% |
JAZZ Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +154.7% | at high | +351.9% |
| 5 y | 5 years | at high | +154.7% | at high | +351.9% |
| alltime | all time | at high | +9558.9% | at high | >+9999.0% |
Jazz Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.22 B(+63.6%) |
| June 2024 | - | $1.36 B(-6.1%) |
| Mar 2024 | - | $1.44 B(-4.2%) |
| Dec 2023 | $1.51 B(+70.9%) | $1.51 B(+12.8%) |
| Sept 2023 | - | $1.34 B(+4.2%) |
| June 2023 | - | $1.28 B(+9.8%) |
| Mar 2023 | - | $1.17 B(+32.5%) |
| Dec 2022 | $881.48 M(+49.0%) | $881.48 M(+5.0%) |
| Sept 2022 | - | $839.36 M(+18.0%) |
| June 2022 | - | $711.26 M(+44.9%) |
| Mar 2022 | - | $490.83 M(-17.0%) |
| Dec 2021 | $591.45 M(-44.1%) | $591.45 M(-12.0%) |
| Sept 2021 | - | $671.78 M(-24.6%) |
| June 2021 | - | $891.40 M(-57.5%) |
| Mar 2021 | - | $2.10 B(+98.3%) |
| Dec 2020 | $1.06 B(+66.0%) | $1.06 B(+42.6%) |
| Sept 2020 | - | $741.94 M(-5.6%) |
| June 2020 | - | $786.08 M(+12.0%) |
| Mar 2020 | - | $701.60 M(+10.1%) |
| Dec 2019 | $637.34 M(+105.8%) | $637.34 M(-19.8%) |
| Sept 2019 | - | $795.17 M(+24.7%) |
| June 2019 | - | $637.74 M(+16.5%) |
| Mar 2019 | - | $547.47 M(+76.8%) |
| Dec 2018 | $309.62 M(-19.8%) | $309.62 M(-38.0%) |
| Sept 2018 | - | $499.02 M(+2.9%) |
| June 2018 | - | $485.08 M(+7.0%) |
| Mar 2018 | - | $453.17 M(+17.4%) |
| Dec 2017 | $386.04 M(+5.5%) | $386.04 M(+52.8%) |
| Sept 2017 | - | $252.62 M(+5.6%) |
| June 2017 | - | $239.21 M(-31.1%) |
| Mar 2017 | - | $347.00 M(-5.2%) |
| Dec 2016 | $365.96 M(-63.0%) | $365.96 M(-0.2%) |
| Sept 2016 | - | $366.57 M(-57.8%) |
| June 2016 | - | $867.97 M(-11.4%) |
| Mar 2016 | - | $979.78 M(-0.9%) |
| Dec 2015 | $988.78 M | $988.78 M(-1.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $998.86 M(+8.4%) |
| June 2015 | - | $921.64 M(+17.8%) |
| Mar 2015 | - | $782.60 M(+14.4%) |
| Dec 2014 | $684.04 M(+7.5%) | $684.04 M(+19.0%) |
| Sept 2014 | - | $575.04 M(+114.4%) |
| June 2014 | - | $268.25 M(+9.1%) |
| Mar 2014 | - | $245.87 M(-61.4%) |
| Dec 2013 | $636.50 M(+64.4%) | $636.50 M(+8.2%) |
| Sept 2013 | - | $588.46 M(+16.7%) |
| June 2013 | - | $504.31 M(+11.9%) |
| Mar 2013 | - | $450.51 M(+16.4%) |
| Dec 2012 | $387.20 M(+371.8%) | $387.20 M(+104.0%) |
| Sept 2012 | - | $189.79 M(+22.8%) |
| June 2012 | - | $154.54 M(-9.4%) |
| Mar 2012 | - | $170.65 M(+107.9%) |
| Dec 2011 | $82.08 M(+83.2%) | $82.08 M(-18.9%) |
| Sept 2011 | - | $101.22 M(-1.2%) |
| June 2011 | - | $102.40 M(+57.4%) |
| Mar 2011 | - | $65.06 M(+45.2%) |
| Dec 2010 | $44.79 M(+187.2%) | $44.79 M(+367.9%) |
| June 2010 | - | $9.57 M(-49.6%) |
| Mar 2010 | - | $19.00 M(+21.8%) |
| Dec 2009 | $15.60 M(-37.4%) | $15.60 M(+27.5%) |
| Sept 2009 | - | $12.23 M(-22.5%) |
| June 2009 | - | $15.77 M(-7.3%) |
| Mar 2009 | - | $17.02 M(-31.7%) |
| Dec 2008 | $24.90 M(-75.8%) | $24.90 M(-50.1%) |
| Sept 2008 | - | $49.91 M(-2.5%) |
| June 2008 | - | $51.20 M(-49.2%) |
| Mar 2008 | - | $100.77 M(-2.1%) |
| Dec 2007 | $102.94 M(+30.4%) | $102.94 M(-14.2%) |
| Sept 2007 | - | $119.97 M(-18.9%) |
| June 2007 | - | $148.00 M(+118.7%) |
| Mar 2007 | - | $67.67 M(-14.3%) |
| Dec 2006 | $78.95 M(+283.0%) | $78.95 M(+283.0%) |
| Dec 2005 | $20.61 M | $20.61 M |
FAQ
- What is Jazz Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Jazz Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of JAZZ is $1.51 B
What is the all time high annual cash & cash equivalents for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual cash & cash equivalents is $1.51 B
What is Jazz Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of JAZZ is $2.22 B
What is the all time high quarterly cash and cash equivalents for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly cash and cash equivalents is $2.22 B
What is Jazz Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, JAZZ quarterly cash and cash equivalents has changed by +$711.83 M (+47.26%)